Literature DB >> 26674451

Liver Cirrhosis is Independently Associated With 90-Day Mortality in ARDS Patients.

Arnaud Gacouin1, Maxime Locufier, Fabrice Uhel, Julien Letheulle, Pierre Bouju, Pierre Fillatre, Yves Le Tulzo, Jean Marc Tadié.   

Abstract

BACKGROUND: In a few studies, cirrhosis has been associated with increased mortality in patients with acute respiratory distress syndrome (ARDS). These studies were, however, conducted mostly before 2000. Over the last 15 years, the prognosis of cirrhotic patients admitted to the intensive care unit (ICU) seems to have improved and major changes in the management of mechanical ventilation (MV) of ARDS have appeared. The aim of this study was to determine whether cirrhosis remains a factor for poor prognosis despite improvements in MV techniques and supportive therapies for ARDS.
METHODS: Retrospective analysis of data recorded from 232 patients (42 with cirrhosis and 290 without cirrhosis) who received lung-protective ventilation for ARDS defined according to American-European Consensus Conference criteria and admitted from 2006 to 2013. Alcohol was the most common aetiology of the cirrhosis. The end point was mortality at day-90 from the diagnosis of ARDS, survival was calculated using the Kaplan-Meier method, and we used a Cox-proportional hazard model to determine whether cirrhosis remained independently associated with mortality after adjustment for other prognostic variables for ARDS described previously. Organ dysfunctions were assessed based on the Sequential Organ Failure Assessment (SOFA) criteria, pulmonary and nonpulmonary dysfunctions were distinguished and compared between cirrhotic and non-cirrhotic patients on the first 3 days of VM.
RESULTS: Comparison of survival curves showed that cirrhotic patients had a poorer 90-day prognosis than non-cirrhotic patients (P = 0.03 by the log-rank test). After adjusted analysis, cirrhosis remained independently associated with mortality at day 90 (adjusted hazard ratio 2.09, 95% CI, 1.27-3.45, P = 0.004). Non-pulmonary SOFA scores were significantly higher in cirrhotic patients than in non-cirrhotic patients on day 1 (P < 0.001), day 2 (P = 0.003), and day 3 (P = 0.002) of MV for ARDS whereas pulmonary SOFA scores did not differ significantly.
CONCLUSIONS: Despite improvements in the management of cirrhotic patients admitted to the ICU and in the management of MV for the treatment of ARDS, cirrhosis remained associated with a poorer prognosis in ARDS patients. The prognosis of cirrhotic patients with ARDS appears related to extrapulmonary organ dysfunctions rather than pulmonary dysfunction.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26674451     DOI: 10.1097/SHK.0000000000000487

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  21 in total

1.  Risk assessments for broncho-pleural fistula and respiratory failure after lung cancer surgery by National Clinical Database Japan.

Authors:  Shunsuke Endo; Norihiko Ikeda; Takashi Kondo; Jun Nakajima; Haruhiko Kondo; Yoshihisa Shimada; Masami Sato; Shinichi Toyooka; Yoshinori Okada; Yukio Sato; Ichiro Yoshino; Morihito Okada; Meinoshin Okumura; Masayuki Chida; Eriko Fukuchi; Hiroaki Miyata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-10-16

2.  An update from the Canadian Association for the Study of the Liver on the management of liver disease during the COVID-19 pandemic.

Authors:  Mayur Brahmania; Stephen Congly; Saumya Jayakumar; Carla S Coffin; Kelly W Burak; Jordan J Feld
Journal:  Can Liver J       Date:  2020-11-17

Review 3.  Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review.

Authors:  Eleni Korompoki; Maria Gavriatopoulou; Rachel S Hicklen; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Despina Fotiou; Kimon Stamatelopoulos; Evangelos Terpos; Anastasia Kotanidou; Carin A Hagberg; Meletios A Dimopoulos; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2021-05-14       Impact factor: 6.072

4.  Neutrophil-to-Lymphocyte Ratio Predicts Death in Acute-on-Chronic Liver Failure Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study.

Authors:  Nicolas Moreau; Xavier Wittebole; Yvan Fleury; Patrice Forget; Pierre-François Laterre; Diego Castanares-Zapatero
Journal:  Shock       Date:  2018-04       Impact factor: 3.454

5.  Impact of large volume paracentesis on respiratory parameters including transpulmonary pressure and on transpulmonary thermodilution derived hemodynamics: A prospective study.

Authors:  Ulrich Mayr; Eugen Karsten; Tobias Lahmer; Sebastian Rasch; Philipp Thies; Benedikt Henschel; Gerrit Fischer; Roland M Schmid; Wolfgang Huber
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240

Review 6.  Hepatic manifestations and impact of COVID-19 on the cirrhotic patient.

Authors:  J A Velarde-Ruiz Velasco; E S García-Jiménez; J M Remes-Troche
Journal:  Rev Gastroenterol Mex (Engl Ed)       Date:  2020-05-27

Review 7.  The liver in times of COVID-19: What hepatologists should know.

Authors:  Ezequiel Ridruejo; Alejandro Soza
Journal:  Ann Hepatol       Date:  2020-05-18       Impact factor: 2.400

8.  Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients.

Authors:  Mario Romero-Cristóbal; Ana Clemente-Sánchez; Patricia Piñeiro; Jamil Cedeño; Laura Rayón; Julia Del Río; Clara Ramos; Diego-Andrés Hernández; Miguel Cova; Aranzazu Caballero; Ignacio Garutti; Pablo García-Olivares; Javier Hortal; Jose-Eugenio Guerrero; Rita García; Rafael Bañares; Diego Rincón
Journal:  Therap Adv Gastroenterol       Date:  2021-06-14       Impact factor: 4.409

9.  COVID-19 and the liver: little cause for concern.

Authors:  Mansoor N Bangash; Jaimin Patel; Dhruv Parekh
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-03-20

10.  Letter: liver disease and COVID-19-not the perfect storm.

Authors:  Rooshi Nathwani; Sujit Mukherjee; Roberta Forlano; Benjamin H Mullish; Nikhil Vergis; Nowlan Selvapatt; Pinelopi Manousou; Shevanthi Nayagam; Maud Lemoine; Ameet Dhar
Journal:  Aliment Pharmacol Ther       Date:  2020-08       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.